Harrow (NASDAQ:HROW) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

Harrow (NASDAQ:HROW) had its target price upped by LADENBURG THALM/SH SH from $64.00 to $66.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s target price points to a potential upside of 69.13% from the company’s current price.

Several other research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Wednesday, October 8th. Lake Street Capital upped their price objective on shares of Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Zacks Research downgraded shares of Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. BTIG Research reissued a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Wednesday, September 24th. Finally, Craig Hallum raised their price objective on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, September 23rd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $71.43.

Harrow Stock Up 0.7%

Shares of NASDAQ:HROW traded up $0.28 during trading on Wednesday, hitting $39.02. The stock had a trading volume of 721,844 shares, compared to its average volume of 551,398. The company has a market capitalization of $1.44 billion, a PE ratio of -156.43 and a beta of 0.19. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The firm’s fifty day moving average is $40.67 and its 200 day moving average is $34.84. Harrow has a 12 month low of $20.85 and a 12 month high of $54.19.

Harrow (NASDAQ:HROW) last issued its quarterly earnings results on Monday, November 10th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.11. The company had revenue of $71.64 million for the quarter, compared to analysts’ expectations of $73.70 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Analysts anticipate that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

Several institutional investors have recently modified their holdings of HROW. Lumbard & Kellner LLC bought a new stake in Harrow in the 3rd quarter worth about $4,281,000. Rafferty Asset Management LLC bought a new stake in shares of Harrow in the third quarter worth approximately $220,000. Quantbot Technologies LP grew its stake in shares of Harrow by 88.8% in the third quarter. Quantbot Technologies LP now owns 16,943 shares of the company’s stock worth $816,000 after acquiring an additional 7,969 shares during the period. MGB Wealth Management LLC bought a new position in Harrow during the third quarter valued at approximately $301,000. Finally, AXQ Capital LP purchased a new stake in Harrow in the third quarter worth approximately $323,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.